Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

NCT ID: NCT03379441

Last Updated: 2017-12-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 126 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-01
• Study Completion Date: 2023-01-01

Brief Summary

Maintainance therapy in patients with unresectable stage III, NSCLC Stage IIIA-B, unresectable, NSCLC, treated with definitive Chemo-Radiotherapy

Detailed Description

This is an Italian multi-center randomized phase II trial (randomization 2:1) of intravenous (IV) MK-3475 (Pembrolizumab) versus observation as a maintenance therapy after chemo-radiotherapy (either concomitant or sequential, regardless of the type of chemotherapy used) in unresectable stage IIIA-IIIB non small cell lung cancer (NSCLC) patients.

Conditions

Non Small Cell Lung Cancer Patients

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Experimental

Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:

• PD,
• unacceptable toxicity,
• investigator choice,
• patients IC withdrawal,
• up to a maximum of 24 months (35 administrations) Experimental

Group Type: EXPERIMENTAL

Pembrolizumab Injectable Product

Intervention Type: DRUG

Pembrolizumab Injectable Product 200 mg Q3W Intravenous

Observation

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Pembrolizumab Injectable Product

Pembrolizumab Injectable Product 200 mg Q3W Intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Be willing and able to provide written informed consent/assent for the trial.
• Be > 18 years of age on day of signing informed consent.
• Have measurable disease based on RECIST 1.1.
• Be willing to provide tissue from a newly obtained core, trucut biopsy or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the PI.
• Have a performance status of 0 or 1 on the ECOG Performance Scale.
• Demonstrate adequate organ function , all screening labs should be performed within 10 days of treatment initiation.
• Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Section 8.14.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
• Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy

Exclusion Criteria

• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
• Has a known history of active Bacillus Tuberculosis (TB)
• Hypersensitivity to pembrolizumab or any of its excipients.
• Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis, or has evidence of interstitial lung disease.
• Has an active infection requiring systemic therapy.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
• Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
• Has known active Hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg] reactive) or Hepatitis C (e.g., HCV ribonucleic acid [RNA] qualitative is detected).
• Has received a live vaccine within 30 days of planned start of study therapy.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Turin, Italy

OTHER

Sponsor Role: lead

Responsible Party

Prof. Silvia Novello

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

CRO Aviano

Aviano, Pordenone, Italy

AOU San Luigi- Department of Oncology

Orbassano, Turin, Italy

Istituto Tumori Giovanni Paolo II

Bari, , Italy

Chieti Università degli Studi "G. D'Annunzio"

Chieti, , Italy

AOU Careggi

Florence, , Italy

IRCCS AO San Martino

Genova, , Italy

Azienda Ospedaliera Papardo

Messina, , Italy

Istituto Clinico Humanitas

Milan, , Italy

Ospedale San Raffaele

Milan, , Italy

Policlinico Modena

Modena, , Italy

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Napoli, , Italy

Policlinico Universitario Campus Biomedico

Roma, , Italy

PO Centrale

Taranto, , Italy

Policlinico Verona Borgo Roma

Verona, , Italy

Countries

Italy

Facility Contacts

Alessandra Bearz, MD

Role: primary

Domenico Galetta, MD

Role: primary

Clara Natoli, MD

Role: primary

Lorenzo Livi, MD

Role: primary

Francesco Grossi, MD

Role: primary

Vincenzo Adamo, MD

Role: primary

Armando Santoro, MD

Role: primary

Vanesa Gregorc, MD

Role: primary

Stefano Cascinu, MD

Role: primary

Alessandro Morabito, MD

Role: primary

Sara Ramella, MD

Role: primary

Salvatore Pisconti, MD

Role: primary

Emilio Bria, MD

Role: primary

Other Identifiers

2016-001252-22

Identifier Type: -

Identifier Source: org_study_id